Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Direct‐acting antivirals withdrawn from the market vs control

All‐cause mortality maximum · adults with chronic hepatitis C

It is very uncertain whether direct‐acting antivirals withdrawn from the market changes all‐cause mortality at maximum compared with control (very low certainty).

1 finding from 1 review

Direct‐acting antivirals for chronic hepatitis C 2017 · Cochrane Headline outcomes only
OR 0.64 [0.23, 1.79]
5 studies · 3045 participants
Very low

Direct‐acting antivirals withdrawn from the market vs control

Proportion of participants with one or more serious adverse event at maximum · adults with chronic hepatitis C

It is very uncertain whether direct‐acting antivirals withdrawn from the market changes proportion of participants with one or more serious adverse event at… compared with control (very low certainty).

1 finding from 1 review

Direct‐acting antivirals for chronic hepatitis C 2017 · Cochrane Headline outcomes only
OR 1.45 [1.22, 1.73]
29 studies · 9229 participants
Very low

Direct‐acting antivirals withdrawn from the market vs control

Proportion of participants with no sustained virological response at maximum · adults with chronic hepatitis C

Direct‐acting antivirals withdrawn from the market may leads to lower proportion of participants with no sustained virological response at… compared with control (low certainty).

1 finding from 1 review

Direct‐acting antivirals for chronic hepatitis C 2017 · Cochrane Headline outcomes only
RR 0.61 [0.55, 0.69]
21 studies · 9075 participants
Low